ReviewOncogene2008
Cadherins and cancer: how does cadherin dysfunction promote tumor progression?
Review in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03620643 (Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours), which is not on this map. Cited by 390 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Who cites it
390 citing papers in PubMed, 2 syntheses or guidelines pooled it, 769 citations in OpenAlex.
- Prognostic and Clinicopathological Significance of E-Cadherin in Pancreatic Cancer Patients: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies.International journal of molecular sciences · 2019Pooled it
- Clusters, fingers, and singles: A mechanical landscape of tumor invasion.PLoS computational biology · 2026Article
- Effect of the hsa-microRNA 200c-3p/ZEB1 loop in epithelial-mesenchymal transition of ovarian cancer cells.Oncology letters · 2026Article
- Low E-cadherin expression is associated with poor prognosis in pulmonal adenocarcinoma.Scientific reports · 2026Article
- Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma.Scientific reports · 2026Article
- Noncoding RNAs in Metabolic Reprogramming of Breast Cancer: Dietary Opportunities and Translational Implications.Experientia supplementum (2012) · 2026Review
- Reduced expression of CDH1 and its prognostic value in pancreatic cancer: a meta-analysis.Archives of medical science : AMS · 2026Review
- Goodbye flat lymphoma biology.FEBS letters · 2025Review
- Clinical importance of E-cadherin deficiency in resectable gastric cancer: A nested case-control study.Oncology letters · 2025Article
- β-Catenin: A Key Molecule in Osteoblast Differentiation.Biomolecules · 2025Review
- DSG3 promotes bladder cancer growth and metastasis via AKT/GSK3β/β-catenin pathway.Journal of translational medicine · 2025Article
- Article
- Treating human cancer by targeting EZH2.Genes & diseases · 2025Review
- A Longitudinal Study of E-Cadherin and Beta-Catenin in Progression of Oral Epithelial Dysplasia.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025Article
- An Overview of Cellular and Molecular Determinants Regulating Chemoresistance in Pleural Mesothelioma.Cancers · 2025Review
- Review
- Role ofFrontiers in oncology · 2025Article
- Identification of metastasis-associated protein 1 (MTA1) as a new molecular marker for canine urothelial carcinoma.Frontiers in veterinary science · 2025Article
- Recognition of Self and Viral Ligands by NK Cell Receptors.Immunological reviews · 2025Review
330 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
It has long been recognized that the cell-cell adhesion receptor, E-cadherin, is an important determinant of tumor progression, serving as a suppressor of invasion and metastasis in many contexts. Yet how the loss of E-cadherin function promotes tumor progression is poorly understood. In this review, we focus on three potential underlying mechanisms: the capacity of E-cadherin to regulate beta-catenin signaling in the canonical Wnt pathway; its potential to inhibit mitogenic signaling through growth factor receptors and the possible links between cadherins and the molecular determinants of epithelial polarity. Each of these potential mechanisms provides insights into the complexity that is likely responsible for the tumor-suppressive action of E-cadherin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.